Published in Nat Rev Gastroenterol Hepatol on January 01, 2010
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. PLoS Pathog (2015) 1.66
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis (2015) 1.59
Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One (2014) 1.43
Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol (2014) 1.36
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol (2010) 1.01
Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol (2010) 1.00
Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One (2014) 0.98
Viral hepatitis a to e in South mediterranean countries. Mediterr J Hematol Infect Dis (2010) 0.95
High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam. PLoS One (2013) 0.90
Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan. J Clin Microbiol (2010) 0.89
The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS One (2014) 0.88
The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol (2014) 0.88
Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep (2014) 0.86
Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol (2016) 0.85
A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol (2015) 0.84
Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis (2014) 0.83
New enzyme-linked immunosorbent assay for detection of antibodies against hepatitis delta virus using a hepatitis delta antigen derived from a Taiwanese clone and comparison to the Abbott radioimmunoassay. Clin Vaccine Immunol (2012) 0.83
Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol (2012) 0.83
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol (2016) 0.82
Life cycle and pathogenesis of hepatitis D virus: A review. World J Hepatol (2013) 0.82
Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil. BMC Infect Dis (2014) 0.82
Hepatitis delta virus: a peculiar virus. Adv Virol (2013) 0.82
Development and evaluation of a baseline-event-anticipation score for hepatitis delta. J Viral Hepat (2014) 0.82
A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians. Hepatology (2016) 0.79
Is liver biopsy still needed in children with chronic viral hepatitis? World J Gastroenterol (2015) 0.78
Hepatitis B and E co-primary infections in an HIV-1-infected patient. J Clin Microbiol (2013) 0.78
Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. J Clin Transl Hepatol (2015) 0.78
Interferon impedes an early step of hepatitis delta virus infection. PLoS One (2011) 0.78
Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. PLoS One (2011) 0.77
Hepatitis D virus infection, replication and cross-talk with the hepatitis B virus. World J Gastroenterol (2014) 0.77
Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One (2014) 0.77
Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med (2015) 0.76
Complete Genome Sequence of a Hepatitis D Virus Genotype 1 Strain Isolated in Guangdong, China. Genome Announc (2015) 0.75
Is Hepatitis Delta infections important in Brazil? BMC Infect Dis (2016) 0.75
Delta hepatitis-related thyroid disease: a unique phenomenon. Prz Gastroenterol (2015) 0.75
Hepatitis D and hepatocellular carcinoma. World J Hepatol (2015) 0.75
Hepatitis Delta Virus Detected in Salivary Glands of Sjögren's Syndrome Patients and Recapitulates a Sjögren's Syndrome-Like Phenotype in Vivo. Pathog Immun (2016) 0.75
Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam. PLoS One (2017) 0.75
Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. PLoS One (2017) 0.75
The Prevalence and Risk Factors of Hepatitis Delta Virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012. Iran J Med Sci (2015) 0.75
High prevalence of chronic hepatitis D virus infection in Eastern Turkey: urbanization of the disease. Arch Med Sci (2016) 0.75
Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. Viruses (2017) 0.75
Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. BMC Infect Dis (2017) 0.75
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
The delta agent. Hepatology (1983) 3.72
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology (2006) 3.14
Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet (1979) 2.29
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95
Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med (1994) 1.84
Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol (2004) 1.76
Production of hepatitis delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line. J Virol (1991) 1.74
Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology (2007) 1.68
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology (2001) 1.46
Delta hepatitis: an update. J Hepatol (2003) 1.46
Hepatitis delta virus. Virology (2006) 1.45
Lamivudine for chronic delta hepatitis. Hepatology (1999) 1.44
Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology (2001) 1.41
Hepatitis D: thirty years after. J Hepatol (2009) 1.41
A multicenter study of viral hepatitis in a United States hemophilic population. Blood (1993) 1.37
Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol (1997) 1.35
Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology (2000) 1.34
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology (2009) 1.32
Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int (2009) 1.29
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology (2000) 1.26
Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis (1996) 1.26
Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol (2007) 1.26
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis (1987) 1.23
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology (2006) 1.22
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology (2009) 1.22
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int (2006) 1.16
The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol (2008) 1.15
Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat (2006) 1.12
Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat (2008) 1.11
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat (2008) 1.11
Review: hepatitis delta. J Gastroenterol Hepatol (1997) 1.10
Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat (2009) 1.08
High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. Am J Trop Med Hyg (2005) 1.07
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology (2006) 1.06
Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. J Virol (2006) 1.05
Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol (2001) 1.04
Hepatitis delta virus inhibits alpha interferon signaling. Hepatology (2009) 1.03
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology (1999) 1.03
High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol (2005) 1.02
Treatment of hepatitis D. J Viral Hepat (2005) 1.02
Famciclovir treatment of chronic delta hepatitis. J Hepatol (2002) 1.01
Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther (2007) 0.99
Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol (2009) 0.98
Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol (2000) 0.97
Delta hepatitis in homosexual men in the United States. Hepatology (1989) 0.97
Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat (2000) 0.97
Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther (2008) 0.96
Prevalence and molecular diversity of hepatitis B virus and hepatitis delta virus in urban and rural populations in northern Gabon in central Africa. J Clin Microbiol (2009) 0.96
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int (2009) 0.96
Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol (2004) 0.95
Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci (2001) 0.95
Ribavirin treatment for chronic hepatitis D: a pilot study. Liver (1994) 0.93
Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther (2005) 0.92
The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees. J Hepatol (1990) 0.92
A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology (1991) 0.91
Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther (2005) 0.90
Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol (2007) 0.89
Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat (2009) 0.89
Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int (2008) 0.88
Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis (2007) 0.87
Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrob Agents Chemother (2005) 0.86
Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol (1999) 0.86
Clearance of chronic HCV infection during acute delta hepatitis. Infection (2007) 0.85
Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis (2006) 0.85
Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology (1998) 0.85
Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol (2005) 0.84
Socioepidemiological data on hepatitis delta in a German university clinic--increase in patients from Eastern Europe and the former Soviet Union. Z Gastroenterol (2003) 0.83
Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg (2000) 0.83
Natural history: the importance of viral load, liver damage and HCC. Best Pract Res Clin Gastroenterol (2008) 0.83
Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. J Med Virol (2006) 0.81
HDV genotypes in the Western Brazilian Amazon region: A preliminary report. Am J Trop Med Hyg (2006) 0.81
Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation (1999) 0.81
Treatment of chronic delta hepatitis with alpha-2 recombinant interferon. J Hepatol (1986) 0.78
HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol (2007) 0.78
Hepatitis D virus infection in Illinois state facilities for the developmentally disabled. Epidemiology and clinical manifestations. Ann Intern Med (1989) 0.78
HDV infection in the Western Pacific region. Prog Clin Biol Res (1991) 0.77
Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. Turk J Gastroenterol (2006) 0.77
[Prevalence of hepatitis B and D serological markers in the Parakanã, Apyterewa Indian Reservation, Pará State, Brazil]. Cad Saude Publica (2007) 0.76
Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. J Hepatol (1991) 0.76
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology (2014) 2.23
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology (2013) 2.12
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 2.12
Microbiologic analysis of peri-pancreatic fluid collected during EUS in patients with pancreatitis: impact on antibiotic therapy. Gastrointest Endosc (2013) 2.10
Endoscopic vacuum-assisted closure of upper intestinal anastomotic leaks. Gastrointest Endosc (2008) 2.06
Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl (2006) 2.04
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication. Nat Cell Biol (2011) 1.99
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology (2007) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology (2012) 1.94
The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol (2008) 1.92
Management of major postsurgical gastroesophageal intrathoracic leaks with an endoscopic vacuum-assisted closure system. Gastrointest Endosc (2009) 1.89
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev (2004) 1.88
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Hepatic gas gangrene following liver transplantation. Liver Transpl (2007) 1.85
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol (2010) 1.80
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int (2009) 1.78
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol (2004) 1.76
Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment. Gut (2011) 1.75
Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology (2010) 1.75
Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes (2004) 1.73
Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology (2010) 1.70
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab (2004) 1.68
Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology (2007) 1.68
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood (2011) 1.67
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int (2013) 1.60
Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol (2008) 1.59
Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology (2010) 1.58
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs (2009) 1.57
CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol (2010) 1.57
Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol (2004) 1.57
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol (2008) 1.56
Clinical pharmacokinetics of everolimus. Clin Pharmacokinet (2004) 1.56
Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology (2012) 1.55
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology (2010) 1.55
Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents. Hepatology (2013) 1.55
Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol (2003) 1.53
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
[Prevalence of circulating autoantibodies in healthy individuals]. Med Klin (Munich) (2002) 1.52
Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology (2005) 1.51
α-1-antitrypsin inhibits acute liver failure in mice. Hepatology (2014) 1.49
Angiopoietin-2 in acute liver failure. Crit Care Med (2012) 1.48
Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl (2008) 1.48
Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr (2013) 1.47
MicroRNAs in the bile of patients with biliary strictures after liver transplantation. Liver Transpl (2014) 1.46
Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis (2013) 1.46
Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology (2008) 1.46
Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol (2011) 1.45
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Endoscopic management of pancreatic pseudocysts or abscesses after an EUS-guided 1-step procedure for initial access. Gastrointest Endosc (2006) 1.43
Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem (2002) 1.42
UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology (2003) 1.42
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res (2004) 1.42
Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology (2006) 1.41
Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology (2009) 1.40
A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int (2015) 1.39
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother (2010) 1.38
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol (2006) 1.36
C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J (2006) 1.35
MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology (2013) 1.32
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer (2003) 1.32
Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology (2004) 1.30
A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell (2013) 1.30
Hepatitis E in Germany--an under-reported infectious disease. Dtsch Arztebl Int (2014) 1.30
Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int (2009) 1.29